Alison Holmes is a Professor of Infectious Diseases at Imperial College London, a Fellow of the Academy of Medical Sciences and an NIHR Senior Investigator. She has a longstanding clinical and research career in infectious diseases with particular interests in antibiotic use, antimicrobial resistance (AMR), epidemiology and public health, particularly in the context of acute care.
She leads a large multi-disciplinary research group and network, with strong collaborations nationally and internationally, and is Director of the National Institute of Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and AMR and the new DHSC funded Centre of Antimicrobial Antimicrobial Optimisation (CAMO) bringing together multidisciplinary expertise to deliver innovative research and technological approaches for antimicrobial optimisation and precision prescribing. She is Co-I on two international collaborations with partners in Vietnam and Thailand to deliver novel cutting-edge technology to diagnose and manage acute febrile illnesses, funded by the Wellcome Trust.
She is President of the International Society for Infectious Diseases (ISID), and sits on a variety of other Executive Committees and Advisory Boards. She serves on WHO Expert groups related to infection prevention, antimicrobial use, AMR, sepsis, and was invited as an international expert at the WHO convened ‘Global Research and Innovation Forum: Towards a Roadmap for the 2019 Novel Coronavirus’, which shaped WHO Country and technical guidance. She is Chair of the Fleming Fund’s Technical Advisory Group (Department of Health and Social Care) and Board Member of the Wellcome Trust’s Surveillance & Epidemiology of Drug-resistant Infections Consortium (SEDRIC). She chairs or sits on numerous international scientific advisory boards, funding panels and editorial boards. Within the NHS, she is an Associate Medical Director, Director of Infection Prevention and Control and a Consultant in Infectious Diseases. She served as an expert member of the Governmental Advisory Committee on AMR and Healthcare Associated Infection for nine years and as a national expert witness for Parliamentary Health and Science and Technology Committees.